Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MDM2 regulates
p53
degradation by functioning as an E3 ubiquitin ligase. The role of MDMX, an MDM2 homolog that lacks E3 ligase activity, in the regulation of
p53
degradation remains incompletely understood and sometime controversial. This confusion is due at least in part to studies of
p53
degradation mainly carried out in in vitro settings, as elimination of either MDM2 or MDMX from mice results in
p53
-dependent embryonic lethality, thus obfuscating in vivo studies of the individual roles of MDM2 and MDMX in
p53
degradation. To overcome this problem, we generated mice expressing an inducible
p53
allele under various MDM2 and MDMX deletion and mutation statuses and studied in vivo
p53
degradation. Degradation of
p53
in vivo was largely prevented in mice and MEF retaining MDM2 but lacking MDMX. While MDM2 and MDMX interacted with
p53
in the absence of each other, they bound
p53
more efficiently as a heterodimer. MDMX, but not MDM2, interacted with
ubiquitin-conjugating enzyme
UbcH5c, an interaction that was essential for MDMX to enable MDM2 E3 ligase activity for
p53
degradation. Grafting the C-terminal residues of MDMX to the C-terminus of MDM2 allowed MDM2 to interact with UbcH5c and enhanced MDM2-mediated
p53
degradation in the absence of MDMX. Together, these data indicate that MDMX plays an essential role for
p53
degradation in vivo by recruiting UbcH5c to facilitate MDM2 E3 ligase function.
...
PMID:MDMX recruits UbcH5c to facilitate MDM2 E3 ligase activity and subsequent p53 degradation in vivo. 3327 68
<< Previous
1
2
3
4